Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1989 Dec;98(4):1360–1364. doi: 10.1111/j.1476-5381.1989.tb12685.x

Endothelium-dependent vasodilator effects of platelet activating factor on rat resistance vessels.

K Kamata 1, T Mori 1, K Shigenobu 1, Y Kasuya 1
PMCID: PMC1854812  PMID: 2611496

Abstract

1. To elucidate the mechanisms of the powerful and long-lasting hypotension produced by platelet activating factor (PAF), its effects on perfusion pressure in the perfused mesenteric arterial bed of the rat were examined. 2. Infusion of PAF (10(-11) to 3 x 10(-10) M; EC50 = 4.0 x 10(-11) M; 95%CL = 1.6 x 10(-11) - 9.4 x 10(-11) M) and acetylcholine (ACh) (10(-10) to 10(-6) M; EC50 = 3.0 +/- 0.1 x 10(-9) M) produced marked concentration-dependent vasodilatations which were significantly inhibited by treatment with detergents (0.1% Triton X-100 for 30 s or 0.3% CHAPS for 90 s). 3. Pretreatment with CV-6209, a PAF antagonist, inhibited PAF- but not ACh-induced vasodilation. 4. Treatment with indomethacin (10(-6) M) had no effect on PAF- or ACh-induced vasodilatation. 5. These results demonstrate that extremely low concentrations of PAF produce vasodilatation of resistance vessels through the release of endothelium-derived relaxing factor (EDRF). This may account for the strong hypotension produced by PAF in vivo.

Full text

PDF
1360

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Camussi G., Aglietta M., Malavasi F., Tetta C., Piacibello W., Sanavio F., Bussolino F. The release of platelet-activating factor from human endothelial cells in culture. J Immunol. 1983 Nov;131(5):2397–2403. [PubMed] [Google Scholar]
  2. Chignard M., Le Couedic J. P., Tence M., Vargaftig B. B., Benveniste J. The role of platelet-activating factor in platelet aggregation. Nature. 1979 Jun 28;279(5716):799–800. doi: 10.1038/279799a0. [DOI] [PubMed] [Google Scholar]
  3. Demopoulos C. A., Pinckard R. N., Hanahan D. J. Platelet-activating factor. Evidence for 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine as the active component (a new class of lipid chemical mediators). J Biol Chem. 1979 Oct 10;254(19):9355–9358. [PubMed] [Google Scholar]
  4. Furchgott R. F. The role of endothelium in the responses of vascular smooth muscle to drugs. Annu Rev Pharmacol Toxicol. 1984;24:175–197. doi: 10.1146/annurev.pa.24.040184.001135. [DOI] [PubMed] [Google Scholar]
  5. Furchgott R. F., Zawadzki J. V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980 Nov 27;288(5789):373–376. doi: 10.1038/288373a0. [DOI] [PubMed] [Google Scholar]
  6. Handley D. A., Van Valen R. G., Melden M. K., Flury S., Lee M. L., Saunders R. N. Inhibition and reversal of endotoxin-, aggregated IgG- and paf-induced hypotension in the rat by SRI 63-072, a paf receptor antagonist. Immunopharmacology. 1986 Aug;12(1):11–16. doi: 10.1016/0162-3109(86)90046-9. [DOI] [PubMed] [Google Scholar]
  7. Kamitani T., Katamoto M., Tatsumi M., Katsuta K., Ono T., Kikuchi H., Kumada S. Mechanism(s) of the hypotensive effect of synthetic 1-O-octadecyl-2-O-acetyl-glycero-3-phosphorylcholine. Eur J Pharmacol. 1984 Mar 2;98(3-4):357–366. doi: 10.1016/0014-2999(84)90284-x. [DOI] [PubMed] [Google Scholar]
  8. Kasuya Y., Masuda Y., Shigenobu K. Hypotensive actions of some analogues of platelet-activating factor (PAF) with higher potencies than natural PAF. Can J Physiol Pharmacol. 1984 Apr;62(4):457–459. doi: 10.1139/y84-073. [DOI] [PubMed] [Google Scholar]
  9. Kasuya Y., Masuda Y., Shigenobu K. Possible role of endothelium in the vasodilator response of rat thoracic aorta to platelet activating factor (PAF). J Pharmacobiodyn. 1984 Feb;7(2):138–142. doi: 10.1248/bpb1978.7.138. [DOI] [PubMed] [Google Scholar]
  10. MCGREGOR D. D. THE EFFECT OF SYMPATHETIC NERVE STIMULATION OF VASOCONSTRICTOR RESPONSES IN PERFUSED MESENTERIC BLOOD VESSELS OF THE RAT. J Physiol. 1965 Mar;177:21–30. doi: 10.1113/jphysiol.1965.sp007572. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Mencia-Huerta J. M., Benveniste J. Platelet-activating factor and macrophages. I. Evidence for the release from rat and mouse peritoneal macrophages and not from mastocytes. Eur J Immunol. 1979 May;9(5):409–415. doi: 10.1002/eji.1830090512. [DOI] [PubMed] [Google Scholar]
  12. Moncada S., Herman A. G., Higgs E. A., Vane J. R. Differential formation of prostacyclin (PGX or PGI2) by layers of the arterial wall. An explanation for the anti-thrombotic properties of vascular endothelium. Thromb Res. 1977 Sep;11(3):323–344. doi: 10.1016/0049-3848(77)90185-2. [DOI] [PubMed] [Google Scholar]
  13. Nichols A. J., Wilson A. C., Hiley C. R. Effects of chemical sympathectomy with 6-hydroxydopamine on cardiac output and its distribution in the rat. Eur J Pharmacol. 1985 Feb 26;109(2):263–268. doi: 10.1016/0014-2999(85)90428-5. [DOI] [PubMed] [Google Scholar]
  14. Randall M. D., Hiley C. R. Detergent and methylene blue affect endothelium-dependent vasorelaxation and pressure/flow relations in rat blood perfused mesenteric arterial bed. Br J Pharmacol. 1988 Dec;95(4):1081–1088. doi: 10.1111/j.1476-5381.1988.tb11742.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Shigenobu K., Masuda Y., Tanaka Y., Kasuya Y. Platelet activating factor analogues: lack of correlation between their activities to produce hypotension and endothelium-mediated vasodilation. J Pharmacobiodyn. 1985 Feb;8(2):128–133. doi: 10.1248/bpb1978.8.128. [DOI] [PubMed] [Google Scholar]
  16. Shigenobu K., Mori T., Kamata K., Kasuya Y. Platelet-activating factor: lack of direct action on guinea pig myocardium and possible transmitter release from cardiac sympathetic nerve endings at high concentrations. Can J Physiol Pharmacol. 1989 Jun;67(6):669–674. doi: 10.1139/y89-107. [DOI] [PubMed] [Google Scholar]
  17. Shigenobu K., Tanaka Y., Maeda T., Kasuya Y. Potentiation by bovine serum albumin (BSA) of endothelium-dependent vasodilator response to acetyl glyceryl ether phosphorylcholine (AGEPC). J Pharmacobiodyn. 1987 May;10(5):220–228. doi: 10.1248/bpb1978.10.220. [DOI] [PubMed] [Google Scholar]
  18. Tanaka S., Kasuya Y., Masuda Y., Shigenobu K. Studies on the hypotensive effects of platelet activating factor (PAF, 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine) in rats, guinea pigs, rabbits, and dogs. J Pharmacobiodyn. 1983 Nov;6(11):866–873. doi: 10.1248/bpb1978.6.866. [DOI] [PubMed] [Google Scholar]
  19. Terashita Z., Imura Y., Nishikawa K. Inhibition by CV-3988 of the binding of [3H]-platelet activating factor (PAF) to the platelet. Biochem Pharmacol. 1985 May 1;34(9):1491–1495. doi: 10.1016/0006-2952(85)90689-6. [DOI] [PubMed] [Google Scholar]
  20. Terashita Z., Imura Y., Takatani M., Tsushima S., Nishikawa K. CV-6209, a highly potent antagonist of platelet activating factor in vitro and in vivo. J Pharmacol Exp Ther. 1987 Jul;242(1):263–268. [PubMed] [Google Scholar]
  21. Tesfamariam B., Halpern W. Endothelium-dependent and endothelium-independent vasodilation in resistance arteries from hypertensive rats. Hypertension. 1988 May;11(5):440–444. doi: 10.1161/01.hyp.11.5.440. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES